Rami Manochakian/X
Jun 3, 2025, 09:56
Rami Manochakian: Tarlatamab vs Chemotherapy in second treatment for advanced SCLC
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared on X:
“Hot Off The Press!
Just published in NEJM in conjunction with presentation at ASCO 2025.
Results of DeLLphi304 phase trial of Tarlatamab vs Chemotherapy in 2nd treatment for advanced Small Cell Lung Cancer.
mOS: 13.6 vs 8.3 months (HR: 0.6)
More Improvement in symptoms with Tarlatamab
≥ Grade 3 AEs: 54% vs 80%
CRS and ICANS mostly grade 1/2.”
Read OncoDaily’s special articles:
Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages, Expectations, and More
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 20, 2025, 00:12
Jul 19, 2025, 21:11
Jul 19, 2025, 20:58
Jul 19, 2025, 20:26
Jul 19, 2025, 20:21